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Lamotrigine is a broad-spectrum antiepileptic drug that blocks sodium channels, thereby inhibiting the pre-synaptic release
of excitatory neurotransmitters. The primary aim of the study was to evaluate lamotrigine add-on therapy and consecutive
monotherapy in patients with epilepsy whose seizures were not controlled by carbamazepine or valproate. One hundred and
twenty six epilepsy patients at 18 centres in Poland were recruited into a lamotrigine substitution study. In all patients, existing
seizures were poorly controlled with valproate (n = 63) or carbamazepine (n = 63) monotherapy. The study consisted of
four phases: (1) a 4-week lamotrigine dose-escalation phase, (2) an 8-week lamotrigine add-on phase, (3) an 8-week carba-
mazepine/valproate withdrawal phase, and (4) an 8-week lamotrigine monotherapy phase.
Of 126 patients recruited into the study, 107 (85%) completed dose-escalation and add-on therapy with lamotrigine and
85 (68%) completed lamotrigine monotherapy. Fifty percent of patients during add-on therapy and 53% during lamotrigine
monotherapy experienced at least 50% reduction in total seizures (responders) compared to the pre-study period. Approximately
20% of patients during add-on therapy and 27% during lamotrigine monotherapy were seizure free. Total well-being was
assessed using a Visual Analogue Scale with 62% of patients during add-on therapy and 60% in lamotrigine monotherapy
reporting improvement in scores. Lamotrigine was generally well tolerated. Treatment was discontinued in 7% because of
adverse events.
In conclusion, lamotrigine is an effective AED in add-on therapy and monotherapy, it is safe and well tolerated, and successful
conversion from add-on to monotherapy can be achieved in many cases. An additive effect between lamotrigine and valproate
was observed.
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INTRODUCTION
Lamotrigine (LTG) is a novel anticonvulsant that in-
hibits the release of glutamate through blockade of
voltage-sensitive sodium channels and through stabi-
lization of the neuronal membrane1. However, this
mechanism alone does not explain the broad clinical
effica y of LTG. It has been suggested that inhibition
of pre-synaptic N-type Ca2+ channels may contribute
to its anticonvulsant effects2.
Approximately 110 worldwide clinical trials in-
volving almost 4000 adults have been completed in
which LTG has been added to existing therapy or has
been administered as monotherapy3. These trials have
demonstrated the effica y of LTG against a wide range
of seizure types in both adults and children and its ef-
fectiveness as add-on therapy for uncontrolled partial
and generalized seizures has been established in many
studies4–8. LTG has also been shown to be well tol-
erated9, 10. Results of monotherapy studies suggested
that LTG is at least as effective as carbamazepine, val-
proate or phenytoin monotherapy and is significantl
better tolerated11–13.
This open study was conducted to examine the effi
cacy and safety of LTG as add-on therapy and consec-
utive monotherapy in adolescents (≥12 years of age)
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and adults whose seizures were not adequately con-
trolled by carbamazepine or valproate.
MATERIALS AND METHODS
Patients
Seizures were classifie according to the Interna-
tional Classificatio of Epileptic Seizures. Adoles-
cents (≥12 years) and adult patients were recruited to
the study if they: (1) had a diagnosis of epilepsy un-
complicated by pseudoseizures; (2) had at least two
seizures in the past 8 weeks; (3) were receiving car-
bamazepine or valproate in the past 8 weeks; (4) had
stable treatment with one antiepileptic drug (AED)
for at least 4 weeks before entering the study (at
least 800 mg of carbamazepine daily in adults and
10 mg kg−1 in adolescents or at least 1000 mg of val-
proate daily in adults and 30 mg kg−1 in adolescents).
All patients provided written informed consent.
Exclusion criteria were pregnancy or exposure to the
risk of pregnancy, breastfeeding, clinically significan
impairment of renal or hepatic function, or treatment
with other medication which in the investigator’s opin-
ion contraindicated entry into the study. Treatment
with oral contraceptives was acceptable.
Study design
The trial was approved by the local research ethics
committee and by the Regulatory Authorities. It was
conducted according to GCP rules and to the princi-
ples of the Declaration of Helsinki.
This was a multi-centre, open, prospective, parallel-
group study conducted in four phases (Fig. 1). All
prospective patients underwent a screening assess-
ment. During the firs phase (weeks 1–4), LTG was
added to the patients’ existing anticonvulsant medica-
tion. In patients taking carbamazepine, doses of LTG
were escalated from 50 mg per day (weeks 1 and 2) to
100 mg per day (weeks 3 and 4), whilst patients tak-
ing valproate received LTG 25 mg on alternate days
(weeks 1 and 2) which was then increased to 25 mg
per day (weeks 3 and 4).
During the second or ‘add-on’ phase (weeks 5–
12), patients were maintained on both LTG and their
original medication (carbamazepine or valproate). In
patients receiving carbamazepine, the dose of LTG
was adjusted to a target dose of 200–500 mg per day.
In patients receiving valproate, LTG doses were con-
tinually escalated (50–75 mg per day, weeks 5 and 6;
100 mg per day, week 7; 150 mg per day, week 8),
reaching 200 mg per day in weeks 9–12.
Phase 3 (weeks 13–20) consisted of a withdrawal
period, during which patients’ original medication was
progressively reduced to achieve LTG monotherapy.
At week 12 the patient was assessed to ensure that
withdrawal of the concomitant standard AED and the
change to LTG monotherapy was appropriate. The
decision was based on treatment effica y (change in
seizure frequency) and a physician’s global evaluation.
In patients taking valproate, doses of LTG were in-
creased to 200–300 mg per day (at week 17) as val-
proate was withdrawn. In the fina study phase (weeks
20–28), all patients received LTG 200–500 mg per day
monotherapy.
Patients also assessed their total well-being every
4 weeks during the study using a Visual Analogue
Scale (VAS). The patient was asked to select a point
on the scale according to their total well-being during
the assessment period. The scale ranged from 0 (poor)
to 10 (good). No supplementary information was sup-
plied to patients about what they should include in
their estimation.
Outcome measures and statistical analyses
The principal measure of effica y was the number of
patients who experienced at least 50% reduction in
seizure frequency during the add-on and monother-
apy phases. For each study phase the mean seizure
frequency is presented with 95% confidenc intervals
(CIs). Comparison of mean seizure frequency between
study phases was performed using Student’s t-test for
dependent samples. Comparison of treatment groups
within each study phase was performed using a chi-
squared test. The number of patients who completed
the add-on phase and the monotherapy phase was also
calculated.
Mean VAS scores for each treatment period are pre-
sented with 95% CIs. Comparison of VAS scores be-
tween treatment groups for each study phase was per-
formed using a chi-squared test. Comparison of VAS
scores between study phases for each treatment arm
was performed using Student’s t-test for dependent
samples. The incidence and nature of adverse events
and their relationship to LTG were recorded.
RESULTS
A total of 126 patients entered the study, 63 who were
taking carbamazepine at baseline and 63 who were
taking valproate. There were no differences between
the treatment groups in terms of gender, age, weight
or seizure type (Table 1).
There was no difference in the distribution of
patients with different seizure types between the car-
bamazepine and valproate treatment groups (Table 2).
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Fig. 1: Study design.
Table 1: Characteristics of patients at entry.
Carbamazepine group n = 63 Valproate group n = 63 Total n = 126
Male/female (%) 54/46 51/49 52/48
Age (yr)
Median (range) 25 (12–52) 19 (12–52) 23.5 (12–52)
Weight (kg)
Median (range) 65 (31–95) 63 (25–105) 64 (25–105)
Seizures from (yr)
Median (range) 10 (1–46) 7 (1–39) 8 (1–46)
Number of seizures in last 8 weeks
Median (range) 8 (2–365) 8 (2–140) 8 (2–365)
Seizure type [n (%)]
Partial seizures with or without 40 (64%) 37(59%) 77(61%)
secondary generalization
Primary generalized seizures 22 (35%) 26 (41%) 48(38%)
Non-classifie 1 (1%) 0 (0%) 1 (1%)
In most patients the aetiology of the seizure was un-
known (n = 64, 51%). However in other patients there
was a history of head trauma (n = 26, 20%), birth
trauma (n = 10, 8%), CNS infection (n = 10, 8%),
cerebrovascular disorder (n = 4, 3%) and brain tu-
mour (n = 1).
Efficacy
Eighty-f ve out of 126 patients (67.5%) completed the
transition from carbamazepine or valproate monother-
apy through add-on treatment to LTG monotherapy. In
the valproate treatment group, 51 out of 63 patients
(81.0%) successfully transferred to LTG monother-
apy whilst in the carbamazepine group, 34 out of 63
(53.1%) were well maintained on LTG monotherapy
(P = 0.001, valproate vs. carbamazepine).
Seizure rates
Add-on period. During the add-on period, 63 out of
126 patients (50.0%) experienced at least 50% reduc-
tion in total seizures when compared to the 8-week
period prior to commencing the study (Table 3). These
patients are classifie as ‘responders’. In the valproate
treatment group, 37 out of 63 patients (58.7%) were re-
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Table 2: Seizure type in observed population.
Seizure type CBZ group VPA group Total
(n) (n) (n)
Simple partial seizures 9 10 19
Complex partial seizures 23 21 44
Partial seizures with
secondary generalization 18 23 42
Absence seizures 6 15 21
Myoclonic seizures 5 6 11
Clonic seizures 2 1 3
Tonic seizures 3 1 4
Tonic–clonic seizures 21 23 44
Atonic seizures 1 2 3
Non-classifie seizures 1 0 1
CBZ, carbamazepine; VPA, valproate.
sponders whilst in the carbamazepine treatment group
26 out of 63 patients (41.3%) were classifie as re-
sponders (P = 0.05: valproate responders vs. carba-
mazepine responders).
There was no statistical difference between the num-
ber of responders who reported primary generalized
seizures at baseline (52.1%) and the responders who
reported partial seizures with or without secondary
generalization (48.1%).
Twenty f ve patients (19.8%) became seizure free
during the LTG add-on period. The majority were re-
ceiving valproate at baseline (19 out of 63, 30.2%)
with significantl fewer patients who were receiving
carbamazepine at baseline achieving seizure-free sta-
tus (6 out of 63, 9.5%; P < 0.01 between treatment
groups).
In the valproate treatment group, mean seizure fre-
quency was reduced from 19.1 (95% CI: 12.6; 25.7)
during the 8-week period prior to entering the study
to 8.6 (95% CI: 3.3; 13.9) during the 8-week add-on
phase (P < 0.001, LTG and valproate vs. valproate
monotherapy, n = 57). Similarly, mean seizure fre-
quency was reduced from 25.6 (95% CI: 8.2; 43.0) to
18.3 (95% CI: 1.6; 35.0) in the carbamazepine group
(n = 50) over the same period.
Monotherapy period. During the monotherapy
period, 67 out of 126 patients (53.2%) were classi-
fie as responders with a >50% reduction in seizure
frequency (Table 3). In the valproate treatment group,
40 out of 63 patients (63.5%) were responders dur-
ing the LTG monotherapy phase whilst 27 out of 63
of the carbamazepine group (42.9%) were responders
(P < 0.05 between treatment groups).
Thirty four out of 126 patients (27.0%) were seizure
free during LTG monotherapy, including 20 out of 63
(31.7%) in the valproate treatment group and 14 out of
63 (22.2%) in the carbamazepine group.
Seizure frequency was also reduced during the
monotherapy phase. In the valproate treatment group,
mean seizure frequency was reduced from 16.8 (95%
CI: 11.6; 22.0) during the 8-week period prior to en-
tering the study to 10.5 (95% CI: −2.5; 23.6) during
the 8-week monotherapy phase (n = 51). Similarly,
mean seizure frequency was reduced from 20.3 (95%
CI: 5.8; 34.8) to 3.9 (95% CI: 1.9; 5.8) in the carba-
mazepine group (P < 0.05, LTG monotherapy vs.
carbamazepine monotherapy; n = 34) over the same
period.
Visual analogue scale
Add-on period. VAS scores were improved in 78 out
of 126 patients (61.9%) between week 4 and week 12
indicating improved well-being. In 36 of these patients
the improvement was>50% and in 42 patients the im-
provement was<50% (Table 4). In the valproate treat-
ment group, 43 out of 63 patients (68.3%) showed im-
proved scores whilst 35 out of 63 (55.6%) patients in
the carbamazepine group showed improved scores.
In the valproate group (n = 57), VAS scores in-
creased from 4.5 (95% CI: 4.0; 5.1) at week 4 to 6.3
(95% CI: 5.7; 6.9) at week 12 (P < 0.001). Sim-
ilarly, scores increased from 5.6 (95% CI: 4.8; 6.3)
to 6.5 (95% CI: 5.8; 7.1) in the carbamazepine group
(n = 50) over the same period (P = 0.015).
Monotherapy period. Seventy f ve out of 126 patients
(59.5%) showed improved VAS scores between week
4 and week 28. In 43 of these patients the improve-
ment was >50% and in 32 patients the improvement
was<50% (Table 4). In the valproate treatment group,
47 out of 63 patients (74.6%) showed improved scores
whilst 28 out of 63 (44.4%) patients in the carba-
mazepine group showed improved scores.
Mean VAS scores increased throughout the duration
of the study. The observed differences were statisti-
cally significan in both treatment groups (Table 5).
Safety
Forty nine out of 126 patients (38.9%) reported ad-
verse events, including 22 out of 63 patients from
the valproate treatment group (34.9%) and 27 out of
63 patients from the carbamazepine treatment group
(42.9%). Adverse events were more frequent during
the add-on period (41 out of 49, 83.7%) than during
monotherapy. The most frequent adverse events were
respiratory tract infection (n = 11, 8.7%) and dizzi-
ness (n = 8, 6.4%). Other adverse events noted were
headache (n = 7, 5.6%), diplopia (n = 5, 4.0%),
tremor (n = 5, 4.0%), somnolence (n = 4, 3.2%),
insomnia (n = 4, 3.2%), nausea (n = 4, 3.2%) and
asthenia (n = 3, 2.4%).
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Table 3: Changes in seizure frequency—number of patients in each subgroup according to the percentage change in seizure
frequency.
LTG add-on therapy LTG monotherapy
vs. vs.
CBZ/VPA monotherapy CBZ/VPA monotherapy
CBZ VPA All CBZ VPA All
Seizure free (100%) 6 19 25 14 20 34
Reduction: >50% to <100% 20 18 38 13 20 33
Reduction: >0% to ≤50% 13 17 30 5 7 12
No change 2 1 3 0 0 0
Increase: >0% to ≤50% 3 1 4 2 2 4
Increase: >50% 6 1 7 0 2 2
Total 50 57 107 34 51 85
CBZ, carbamazepine; VPA, valproate.
Table 4: Changes in VAS scores—number of patients in subgroups according to the percentage change in VAS.
Add-on therapy (week 12) LTG monotherapy (week 28)
vs. vs.
Escalation period (week 4) Escalation period (week 4)
CBZ VPA All CBZ VPA All
Improvement ≥100% 9 17 26 7 19 26
Improvement >50% to <100% 4 6 10 5 12 17
Improvement >0% to ≤50% 22 20 42 16 16 32
No change 2 1 3 1 1 2
Deterioration >0% to ≤50% 11 11 22 4 3 7
Deterioration >50% 2 2 4 1 0 1
Total 50 57 107 34 51 85
CBZ, Carbamazepine; VPA, Valproate; VAS, Visual Analogue Scale.
Treatment was discontinued in nine patients (7.1%)
because of adverse events. Dosage adjustment was
performed in f ve patients (4.0%). Rash was the
most frequent single reason for discontinuation (n =
5, 4.0%) with all cases developing within 8 weeks of
commencing treatment. One patient developed a short-
term rash that lasted 10 hours, and was not removed
from the study. In all cases the rash resolved com-
pletely upon discontinuation of LTG. There was a sin-
gle serious adverse event. A female patient receiving
valproate (800 mg) and LTG (250 mg) was hospital-
ized due to diplopia and dizziness. These symptoms
resolved after LTG discontinuation.
DISCUSSION
Over the past 15–20 years, important advances have
been made in the diagnosis and treatment of epilepsy
and epileptic syndromes. The recent availability of
several new antiepileptic drugs has enhanced the man-
agement of patients with epilepsy. Treatment should
be initiated with monotherapy and doses slowly esca-
lated to achieve the target level without causing signif-
icant adverse effects. If this does not achieve adequate
seizure control, further dose increases may be needed.
If the treatment is still unsuccessful, monotherapy with
an alternative drug should be prescribed14. Studies
show that monotherapy, either as an initial treatment or
as alternative treatment (through an add-on period and
consecutive secondary monotherapy), provides ade-
quate control in approximately 70% of adult patients
with partial epilepsy15.
Carbamazepine and valproate remain the first-lin
treatments of epilepsy in Poland. We performed an
open, multi-centre, prospective trial of LTG in patients
with treatment-resistant epilepsy who were receiving
monotherapy treatment with carbamazepine or val-
proate.
Our study demonstrates that LTG is effective in
add-on therapy and consecutive monotherapy in ado-
lescents and adults with epilepsy. Over 50% of patients
had a reduction in seizure frequency of 50% or
more and over 25% were seizure free during LTG
monotherapy. These results support and extend the
conclusions from previous add-on and withdrawal to
LTG monotherapy studies. Brodie reported that 50%
of patients experienced at least a 50% reduction in
seizure frequency with add-on LTG, and 19% of evalu-
able patients were seizure free with LTG monother-
apy16.
In the present study, addition of LTG in patients
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Table 5: Mean VAS scores in chosen treatment periods.
Valproate group, n = 51 Carbamazepine group n = 34
Mean VAS score (CI 95%) Mean VAS score (CI 95%)
Week 4 4.4 (3.8; 5.0) 5.8 (4.9; 6.6)
Week 12 6.5 (5.9; 7.1) 7.3 (6.7; 7.9)
Week 28 7.9∗† (7.5; 8.4) 7.5∗ (6.7; 8.3)
VAS scores were recorded at the end of the lamotrigine dose escalation phase (week 4), the end of the lamotrigine add-on phase (week 12) and
the end of the lamotrigine monotherapy phase (week 28).
∗ P < 0.001 compared to week 4;
† P < 0.001 compared to week 12.
receiving valproate monotherapy produced a signifi
cantly better response than addition of LTG in patients
receiving carbamazepine monotherapy. This findin is
also consistent with previous reports16–18.
The primary aim of AED therapy is to establish a
therapeutic dose that provides the best seizure control
with minimal side effects. When used in combination
as add-on therapy, AEDs can cause a complex array of
pharmacokinetic and pharmacodynamic drug interac-
tions, which can easily disturb the established balance
and may cause patients to experience an increase in
seizures or an increase in drug-related toxicity. Ideally,
treatment of epilepsy is achieved with monotherapy. In
the present study we have confirme that withdrawal
of carbamazepine or valproate can be performed suc-
cessfully, with over two out of three patients achiev-
ing LTG monotherapy, and more than half classifie
as responders. A simultaneous increase in VAS scores
in both treatment groups also indicates an improved
sense of well-being from the perspective of the patient.
The results of this study also indicate that LTG
is well tolerated when added to existing AED ther-
apy followed by AED withdrawal. Conversion to LTG
monotherapy from a polytherapy regimen with carba-
mazepine or valproate led to improved tolerance. In
the present study the frequency of rash was slightly
lower than that previously observed in add-on LTG
therapy19. All cases were non-serious and occurred
during the firs 8 weeks of treatment when patients
were receiving add-on therapy and all disappeared,
either spontaneously (in one case) or after LTG dis-
continuation (in f ve cases). In general, the risk of rash
increases when the recommended starting dose or the
rate of dose escalation are exceeded. The LTG dosage
regimen in the current study is consistent with cur-
rently recommended guidelines and was strictly ad-
hered to.
Optimizing therapy requires selection of the AED
that has been shown to be the most effective for
the patient’s type of seizures and epileptic syndrome,
and that has the most favourable safety profile Some
patients require treatment with more than one agent,
but alternative monotherapy regimens should be tried
firs if the initial AED is ineffective or causes un-
acceptable side effects20. More complex issues con-
cern women of childbearing age. Optimal AED se-
lection in women with epilepsy requires reproductive
health issue knowledge, such as contraceptive choice
and specifi teratogenic risks21, 22. The effica y of
oral hormonal contraceptives is impaired by concomi-
tant use of liver enzyme-inducing agents such as car-
bamazepine, phenytoin, barbiturates, and topiramate.
Valproate and LTG do not reduce levels of the oral
contraceptive hormones and therefore should not in-
crease the risk of their failure21. Both carbamazepine
and valproate are known to cause neural tube defects
(0.5–1.0% and 1–2%, respectively)23, 24. On the other
hand, the animal reproductive toxicology studies are
quite favourable for LTG. Although there is no evi-
dence of teratogenicity from pre-clinical studies, the
Lamotrigine Pregnancy Registry was established to
prospectively collect prenatal LTG exposure and preg-
nancy outcome data25.
In summary, this study shows that LTG is an effec-
tive AED in add-on therapy and monotherapy and that
it is well tolerated. In most cases conversion from ad-
junctive therapy to LTG monotherapy can be achieved
successfully.
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